Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

Lisa Miller
Published: Wednesday, Oct 04, 2017
Mehrdad Alemozaffar, MD

Mehrdad Alemozaffar, MD

Adjuvant therapy with tyrosine kinase inhibitors (TKIs) for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network (NCCN) guidelines, yet this approach is still controversial, with many physicians believing there are not yet enough data in support of its use.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication